(177)Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials

SIMPLE SUMMARY: Neuroendocrine Tumors are rare cancers with limited therapeutic options. Functioning NETs could produce bioactive peptides leading to a specific syndrome that impacts on patients’ quality of life and also on survival—F-NETs patients who are refractory to SSA respond to 177LU-PRRT wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bongiovanni, Alberto, Nicolini, Silvia, Ibrahim, Toni, Foca, Flavia, Sansovini, Maddalena, Di Paolo, Arianna, Grassi, Ilaria, Liverani, Chiara, Calabrese, Chiara, Ranallo, Nicoletta, Matteucci, Federica, Paganelli, Giovanni, Severi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776442/
https://www.ncbi.nlm.nih.gov/pubmed/36551507
http://dx.doi.org/10.3390/cancers14246022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776442/
https://www.ncbi.nlm.nih.gov/pubmed/36551507
http://dx.doi.org/10.3390/cancers14246022

Ejemplares similares